Search results for " Angioedema"

showing 10 items of 121 documents

A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor.

2011

In hereditary angioedema with normal C1-inhibitor two different missense mutations of codon p.Thr328* in the coagulation factor 12 gene have been reported in some families. In this study a novel factor 12 gene mutation, the deletion of 72 base pairs (bp) (c.971_1018+24del72*), was identified in a family of Turkish origin, in two sisters with recurrent skin swellings and abdominal pain attacks and in their symptom-free father. This deletion caused a loss of 48 bp of exon 9 (coding amino acids 324* to 340*) in addition to 24 bp of intron 9, including the authentic donor splice site of exon 9. The large deletion of 72 bp was located in the same F12 gene region as the missense mutations p.Thr32…

AdultMaleFactor XII DeficiencyTurkeyImmunologyDNA Mutational AnalysisMutation MissenseGene mutationmedicine.disease_causeC1-inhibitorExonImmunology and AllergyMedicineMissense mutationHumansHereditary Angioedema Type IIISequence DeletionGeneticsMutationAngioedemabiologybusiness.industryAngioedemas HereditaryExonsmedicine.diseaseMolecular biologyIntronsPedigreeHereditary angioedemaFactor XIIMutationbiology.proteinFemalemedicine.symptombusinessComplement C1 Inhibitor ProteinClinical immunology (Orlando, Fla.)
researchProduct

Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant)

2006

Background In hereditary angioedema, bradykinin is assumed to be the most important mediator of edema formation. Objective To assess whether the selective bradykinin receptor-2 antagonist Icatibant is effective in acute edema attacks of hereditary angioedema. Methods In this uncontrolled pilot study, 15 patients with 20 attacks were treated with Icatibant. The attacks were analyzed by using a standardized and validated visual analog scale measurement and compared with historical data of untreated attacks. Plasma bradykinin concentration was measured before and 4 hours after intravenous Icatibant treatment. Results Symptom intensity decreased within 4 hours after administration of Icatibant;…

AdultMaleImmunologyBradykininPilot ProjectsBradykininchemistry.chemical_compoundEcallantideIcatibantBradykinin B2 Receptor AntagonistsHumansImmunology and AllergyMedicineAngioedemaBradykinin receptorBradykinin B2 Receptor AntagonistsAngioedemabusiness.industryGenetic Diseases InbornMiddle Agedmedicine.diseasechemistryAnesthesiaAcute DiseaseHereditary angioedemaFemalemedicine.symptomB2 Bradykinin Receptorbusinessmedicine.drugJournal of Allergy and Clinical Immunology
researchProduct

Modification of Peripheral Blood T-Lymphocyte Surface Receptors and Langerhans Cell Numbers in Hereditary Angioedema

1986

Hereditary angioedema (HAE) is a disease related to a complement disorder, namely a deficiency of C1 esterase inhibitor. Complement-split products are implicated in the regulation of the immune response, and we have compared some immunologic parameters between HAE and normal individuals. T-lymphocytes with receptors for IgG were increased in HAE, but no difference in T-cell suppressor activity for B-cells was detected. Furthermore, increased IgG receptor expression was not accompanied by any significant changes in the ratios of OKT4- and OKT8-defined antigens. Numbers of peripheral mononuclear cells (MNC) detected by alpha-naphthyl acetate esterase (ANAE) staining positivity were not signif…

AdultMaleLangerhans cellT-LymphocytesReceptor expressionReceptors Antigen T-CellFluorescent Antibody TechniqueCell CountT-Lymphocytes RegulatoryPeripheral blood mononuclear cellMonocytesLeukocyte CountImmune systemmedicineHumansAngioedemaReceptorSkinChemistryAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseComplement systemmedicine.anatomical_structureLangerhans CellsHereditary angioedemaImmunologyFemaleCell activationAmerican Journal of Clinical Pathology
researchProduct

Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks

2019

Background For the prevention of attacks of hereditary angioedema (HAE), the efficacy and safety of subcutaneous human C1-esterase inhibitor (C1-INH[SC]; HAEGARDA, CSL Behring) was established in the 16-week Clinical Study for Optimal Management of Preventing Angioedema with Low-Volume Subcutaneous C1-Inhibitor Replacement Therapy (COMPACT). Objective To assess the long-term safety, occurrence of angioedema attacks, and use of rescue medication with C1-INH(SC). Methods Open-label, randomized, parallel-arm extension of COMPACT across 11 countries. Patients with frequent angioedema attacks, either study treatment-naive or who had completed COMPACT, were randomly assigned (1:1) to 40 IU/kg or …

AdultMalePediatricsmedicine.medical_specialtyAdolescentInjections SubcutaneousAttack rateC1-inhibitor03 medical and health sciencesYoung Adult0302 clinical medicinemedicineLong term outcomesImmunology and AllergyHumans030212 general & internal medicineddc:610Adverse effectChildAgedbiologyAngioedemabusiness.industryIncidence (epidemiology)Angioedemas HereditaryMiddle Agedmedicine.diseaseOptimal managementTreatment Outcome030228 respiratory systemHereditary angioedemabiology.proteinFemalemedicine.symptombusinessComplement C1 Inhibitor Protein
researchProduct

A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy

2014

Introduction Hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE type I) or dysfunction (C1-INH-HAE type II) is a rare disease characterized by recurrent episodes of edema with an estimated frequency of 1:50,000 in the global population without racial or gender differences. In this study we present the results of a nationwide survey of C1-INH-HAE patients referring to 17 Italian centers, the Italian network for C1-INH-HAE, ITACA. Methods Italian patients diagnosed with C1-INH-HAE from 1973 to 2013 were included in the study. Diagnosis of C1-INH-HAE was based on family and/or personal history of recurrent angioedema without urticaria and on antigenic and/or functional C1-INH def…

AdultMalePediatricsmedicine.medical_specialtyAdolescentPopulationNationwide surveyC1-inhibitorYoung AdultmedicineHumansGenetics(clinical)C1 inhibitor; C4; Hereditary angioedema; Adolescent; Adult; Angioedemas Hereditary; Female; Humans; Italy; Male; Middle Aged; Young Adult; Medicine (all); Genetics (clinical); Pharmacology (medical)Pharmacology (medical)Young adulteducationGenetics (clinical)C4Medicine(all)Hereditary angioedemaeducation.field_of_studyC1 inhibitorAngioedemabiologybusiness.industryResearchMedicine (all)Angioedemas HereditaryAngioedemasGeneral MedicineMiddle Agedbacterial infections and mycosesmedicine.diseaseSettore MED/16 - ReumatologiaHereditaryItalyHereditary angioedemabiology.proteinFemalemedicine.symptomDifferential diagnosisbusinessRare diseaseOrphanet Journal of Rare Diseases
researchProduct

Asphyxiation by laryngeal edema in patients with hereditary angioedema.

2000

Objective To describe the occurrence of fatal laryngeal edema in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Patients and Methods We describe 6 patients from various regions of Germany who died from laryngeal edema within the last 10 years. Furthermore, we conducted a retrospective survey of 58 patients with hereditary angioedema, originating from 46 affected families. The data were obtained from the attending physicians and from the patients' relatives. Results Among the 6 reported patients, aged 9 to 78 years, hereditary angioedema had been diagnosed in 3 and was undiagnosed in 3. None of them had an emergency cricothyrotomy or received C1 inhibitor concen…

AdultMalePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentComplement C1 Inactivator ProteinsLaryngeal EdemaC1-inhibitorLaryngeal DiseasesEcallantideAsphyxiaEdemamedicineHumansCricothyrotomyAngioedemaChildAgedRetrospective StudiesFirst episodeAsphyxiabiologybusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseAnesthesiaHereditary angioedemabiology.proteinFemalemedicine.symptombusinessmedicine.drugMayo Clinic proceedings
researchProduct

Helicobacter pylori Infection as a Triggering Factor of Attacks in Patients with Hereditary Angioedema

2007

  Udgivelsesdato: 2007-Jun BACKGROUND: Helicobacter pylori infection is considered among the causative factors of urticaria and angioedema. Having conducted a study on 65 patients, Hungarian authors reported in 2001 that successful eradication of H. pylori is followed by a significant reduction in the number of attacks in patients with hereditary angioedema (HAE). The present study aimed to reinvestigate the relationship between H. pylori infection and the attack rate in the framework of an international collaborative study. MATERIALS AND METHODS: Within the framework of the PREHAEAT project launched by the European Union, further 152 patients were studied in seven collaborating centers, an…

AdultMalePeptic UlcerHelicobacter pylori infectionmedicine.medical_specialtyAdolescentImmunologyAttack ratemacromolecular substancesHelicobacter InfectionsDisease severityInternal medicinemedicineImmunology and AllergyHumansmedia_common.cataloged_instanceIn patientAttack frequencyAngioedemaEuropean unionChildAgedmedia_commonClinical Trials as TopicHelicobacter pyloribiologyAngioedemabusiness.industryGastroenterologyGeneral MedicineMiddle AgedHelicobacter pylorimedicine.diseasebiology.organism_classificationInfectious DiseasesChild PreschoolGastritisHereditary angioedemaImmunologyFemalemedicine.symptombusinessHelicobacter
researchProduct

Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients

2008

Background Hereditary angioedema (HAE) due to C1 inhibitor deficiency is clinically characterized by relapsing skin swellings, abdominal pain attacks, and life-threatening upper airway obstruction. Treatment with androgens prevents attacks for those with this condition. Objective To examine the benefits and risks of long-term treatment with danazol. Methods Data were generated retrospectively from 118 German and Danish patients who had HAE due to C1 inhibitor deficiency and were treated with danazol from 2 months to 30 years. The frequency and severity of acute attacks were registered before and during danazol treatment, and adverse effects to the treatment were noted. Data were collected b…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAbdominal painPediatricsImmunologyDose-Response Relationship ImmunologicRisk AssessmentSeverity of Illness IndexEcallantideSeverity of illnessmedicineHumansImmunology and AllergyAdverse effectDepression (differential diagnoses)Retrospective StudiesDanazolbusiness.industryDanazolAngioedemas HereditaryEstrogen AntagonistsMiddle Agedmedicine.diseaseSurgeryDiscontinuationHereditary angioedemaFemalemedicine.symptombusinessFollow-Up Studiesmedicine.drugAnnals of Allergy, Asthma & Immunology
researchProduct

Psychometric Field Study of Hereditary Angioedema Quality of Life Questionnaire for Adults:HAE-QoL

2016

Background: Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) may affect health-related quality of life (HRQoL). A specific HRQoL questionnaire for adult patients with C1-INH-HAE, the HAE-QoL, has recently been developed in Spain. Objective: The objective of this study was to perform a cross-cultural validation and psychometric study of the HAE-QoL in an international setting. Methods: Cross-cultural adaptation of the Spanish HAE-QoL draft version and an international rating phase with experts were performed. The resultant version of the HAE-QoL, a clinical questionnaire, and Short Form 36-item Health Survey Version 2.0 (SF-36v2) were pilot tested internationally. Item reduc…

AdultMaleQuality of lifemedicine.medical_specialtyCIENCIAS MÉDICAS Y DE LA SALUDPsychometricsPsychometricsIntraclass correlationMedicina ClínicaSF-36v203 medical and health sciences0302 clinical medicineCronbach's alphaSurveys and QuestionnairesmedicineHumansImmunology and AllergyAdults030212 general & internal medicineAlergiasHAE-QoLPsychiatryDisease-specificHereditary angioedemaC1 inhibitorbusiness.industryQuestionnaireAngioedemas Hereditarymedicine.diseaseMental healthhumanitiesExploratory factor analysis030228 respiratory systemConvergent validityValidation studiesItem reductionHereditary angioedemaQuality of LifeFemalebusinessPsychometric
researchProduct

Hereditary angioedema with normal C1-inhibitor activity in women.

2000

Summary Background Hereditary angioedema (HAE) is a well defined autosomal dominant disease (Mendelian Inheritance in Man #106100) that results from an inherited deficiency of C1 (the activated first component of complement) inhibitor function. We report an unusual variant of HAE with normal biochemical C1-inhibitor function, occurring only in women. Methods We screened 574 patients with recurrent angioedema of the skin for presence of HAE. 283 patients were selected, in whom angioedema was associated with abdominal pain attacks or recurrent life-threatening episodes of upper-airway obstruction, or both, rather than with urticaria. We measured C1-inhibitor concentration and functional activ…

AdultMaleX ChromosomeAdolescentGenetic LinkageComplement C1 Inactivator ProteinsC1-inhibitorEcallantideSex FactorsRecurrenceTerminology as TopicmedicineHumansHereditary Angioedema Type IIISex RatioFamily historyAngioedemaChildDominance (genetics)Genes DominantAngioedemabiologybusiness.industryAutosomal dominant traitComplement C4General MedicineMiddle Agedmedicine.diseaseAbdominal PainPedigreeAirway ObstructionImmunologyHereditary angioedemaMutationbiology.proteinFemalemedicine.symptombusinessmedicine.drugLancet (London, England)
researchProduct